EditorialVivek Ramaswamy, the biotech millionaire turned Republican presidential candidate, greets Iowa voters at the Veterans Freedom Center in Dubuque, Iowa, on June 15, 2023. (Jordan Gale/The New York Times)
EditorialVivek Ramaswamy, the biotech millionaire turned Republican presidential candidate, greets Iowa voters at the Veterans Freedom Center in Dubuque, Iowa, on June 15, 2023. (Jordan Gale/The New York Times)
EditorialVivek Ramaswamy, the biotech millionaire turned Republican presidential candidate, greets Iowa voters at the Veterans Freedom Center in Dubuque, Iowa, on June 15, 2023. (Jordan Gale/The New York Times)
EditorialVivek Ramaswamy, the biotech millionaire turned Republican presidential candidate, in his campaign bus after a meet-and-greet in Bettendorf, Iowa, June 15, 2023. (Jordan Gale/The New York Times)
EditorialVivek Ramaswamy, the biotech millionaire turned Republican presidential candidate, in his campaign bus after a meet-and-greet in Bettendorf, Iowa, June 15, 2023. (Jordan Gale/The New York Times)
EditorialVivek Ramaswamy, the biotech millionaire turned Republican presidential candidate, in his campaign bus after a meet-and-greet in Bettendorf, Iowa, June 15, 2023. (Jordan Gale/The New York Times)
EditorialPresident Joe Biden speaks to reporters before boarding Air Force One at Joint Base Andrews in Maryland, Sept. 12, 2022. (Sarah Silbiger/The New York Times)
EditorialA Cassava Sciences nameplate on the exterior of an office building in Austin, Texas, April 18, 2022. (Ilana Panich-Linsman/The New York Times)
EditorialA $100 million complex for artificial intelligence and biotech companies being built by the University of Toronto, in downtown Toronto, March 9, 2022. (Brendan Ko/The New York Times)
EditorialMio funding by the federal government: The Hamburg-based biotech company Evotec is developing a drug against Covid-19, Hamburg, Germany - 04 Jan 2022
EditorialUS House Select Subcommittee on the Coronavirus Crisis hybrid hearing on Examining Emergent Biosolutions Failure to Protect Public Health and Public Funds
EditorialUS House Select Subcommittee on the Coronavirus Crisis hybrid hearing on Examining Emergent Biosolutions Failure to Protect Public Health and Public Funds
EditorialRobert Kramer, chief executive officer of Emergent BioSolutions, testifies remotely via videoconference during a House Select Subcommittee on the Coronavirus Crisis hearing in the Rayburn House Office Building on Capitol Hill in Washington on Wednesday, May 19, 2021. (Stefani Reynolds/The New York Times)
EditorialA photo provided by Joe Andrucyk/Office of Governor Larry Hogan shows the chief executive of Emergent BioSolutions, Robert Kramer, right with glasses, giving Gov. Larry Hogan of Maryland, center, a tour of the company’s Baltimore plant on Feb. 8, 2021. (Joe Andrucyk/Office of Governor Larry Hogan via The New York Times)
Loading